Posted On: 09/22/2015 10:37:57 AM
Post# of 72447
This was posted on facebook under the ICAAC status:
"Important points to note from this Poster:
Although Brilacidin is from a brand new class of antibiotics, its distribution throughout the body, and its activity at the site of infection, have been described by standard mathematical models. This means that predictions can be made around the safety and efficacy of different dosing regimens based on demographic characteristics, such as body size, gender, and age. Because body weight did not seem to affect the level of brilacidin or its activity, we have an opportunity to give a fixed dose to every adult, or at least to the heavier ones (>90kg), rather than a different dose to each adult based on weight. This means that there is less of a risk of a "dosing error”—This is important in today’s health care system, as dosing errors can lead to either lower drug levels, which can decrease efficacy, or to higher drug levels, which can increase adverse reactions."
"Important points to note from this Poster:
Although Brilacidin is from a brand new class of antibiotics, its distribution throughout the body, and its activity at the site of infection, have been described by standard mathematical models. This means that predictions can be made around the safety and efficacy of different dosing regimens based on demographic characteristics, such as body size, gender, and age. Because body weight did not seem to affect the level of brilacidin or its activity, we have an opportunity to give a fixed dose to every adult, or at least to the heavier ones (>90kg), rather than a different dose to each adult based on weight. This means that there is less of a risk of a "dosing error”—This is important in today’s health care system, as dosing errors can lead to either lower drug levels, which can decrease efficacy, or to higher drug levels, which can increase adverse reactions."
(0)
(0)
